Last reviewed · How we verify
NCT05933876
The Impact of Radiotherapy on Oligometastatic Cancer
trial testing To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR). in Metastasis in 2,000 participants. Currently enrolling.
31 December 2037
Quick facts
| Lead sponsor | Institut Investigacio Sanitaria Pere Virgili |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 December 2022 |
| Primary completion | 31 December 2037 |
| Estimated completion | 31 December 2037 |
| Sites | 21 locations across Spain |
Drugs / interventions tested
- To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).
- To propose a diagnostic test to determine the effectiveness of SABR.
- To propose a diagnostic test for Oligometastatic Cancer (OC).
Conditions studied
- Metastasis — all drugs for Metastasis →
- Metastatic Breast Cancer — all drugs for Metastatic Breast Cancer →
- Metastatic Prostate Cancer — all drugs for Metastatic Prostate Cancer →
- Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →
Sponsor
Institut Investigacio Sanitaria Pere Virgili — full company profile →
Who can join
18 and older, any sex, with Metastasis or Metastatic Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05933876
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastasis
Currently open trials in the same condition.
- NCT06787014 — Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and · recruiting
- NCT06863272 — A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Re · Phase 1, PHASE2 · recruiting
- NCT07040657 — Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometria · NA · recruiting
- NCT07154563 — Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Ca · recruiting
- NCT06362369 — A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy · Phase 1, PHASE2 · recruiting
Other Institut Investigacio Sanitaria Pere Virgili trials
Trials by the same sponsor.
- NCT07205978 — Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis · active not recruiting
- NCT07124923 — Continuous Care Intervention in Primary Care to Improve Type 2 Diabetes Control in Terres de l'Ebre, Catalonia · NA · recruiting
- NCT07427056 — Impact of the War in Ukraine on the Mental Health of Refugees Residing in Spain · completed
- NCT06775509 — Optical Quality of the Cornea in Orthokeratology · NA · active not recruiting
- NCT06395246 — Circulating Microvesicles Regulating Metabolic Homeostasis in Obesity After Caloric Restriction Programs · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05933876 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Investigacio Sanitaria Pere Virgili
- Last refreshed: 18 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05933876.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing